Progress Toward Appropriate Medicines for Childhood TB

Cherise Scott Director, Pediatric Programs <u>cherise.scott@tballiance.org</u> October 27, 2014 Childhood TB Subgroup Meeting









The Problem

Children with TB are the neglected of the neglected

- The market for pediatric medicines is "broken" and needs repair and requires:
 - Better estimates of how many children get TB and where they are located
 - Clarity on drug registration pathways
 - Consistency of treatment policies and practices
 - Prioritization by governments, donors, in-country stakeholders (i.e., NGOs, private sector) and drug companies





Overview

Speeding Treatments to End Pediatric TB (STEP)-TB Unmet Medical Need


Not enough kids being treated – and not being treated appropriately

<u>Goal</u>

Increase access to correctly dosed, properly formulated, affordable, high quality pediatric TB medicines

Implementing Partner





Three Key Outcomes

Scope of Pediatric Initiative

Market Catalyzed

- Market Research--How many patients? Where? How are they currently being treated?
- Manufacturers' commitments
- Momentum and visibility

Drugs Available

- Correct dosage & dispersible form for HRZ, HR, and E
- Shorten gap between approval of adult products vs. pediatric products

Uptake Influenced

- Global treatment guidelines adopted
- National guidelines developed and health workers trained
- Child TB included in NSPs and Global Fund Concept Notes
- Funding committed for product and implementation

Timeline for New First-Line Pediatric Formulations:

Q2 2015: Dosage guidelines for children <5kg

Q1 2014: Initiate discussions with GDF, Global Fund, other donors

2013:

Project Launch Q2 2014:Three manufacturing partners secured

Q4 2014:

Countries

of child TB

quantify cases

Q1 2015:

Manufacturers submit for WHO PQ and local registration Q2/3 2015: Firstline FDC products available to procure through GDF and/or Importation waivers

Q2 2016: All firstline products WHO prequalified and available in the market

Market Catalyzed

STEP-TB Project aims to achieve the following goals

- Conduct market studies to understand the fundamental size, scope and dynamics of the pediatric TB market
- Collaborate with 2 to 3 manufacturers to produce high quality HRZ, HR, and E in the correct dosages and formulations for children on a global scale
- Build relationships with local manufacturers meeting international quality standards where appropriate
- Link to markets (countries and global purchaser Global Drug Facility)
- Disseminate market data & regulatory pathway findings to countries, researchers, manufacturers



Market Catalyzed

Progress to Date

- Market Intelligence
 - Modeling of the pediatric TB Burden (WHO, Sheffield University/Imperial College, Yale/Harvard)
 - Understanding the role of the non-NTP sector and the extent of underreporting in target pediatric TB Markets (Inventory Protocol Workshop)
 - Market sizing tool to synthesize data and refine estimates
 - Country landscaping pulling information from multiple sources to fully understand the policy, supply management/procurement, and regulatory process of the 22 HBCs
- 3 manufacturer commitments secured; facilitating relationships with global manufacturers and local manufacturers/distributors in key markets
- Web portal launched; Pediatric Advisory Group established; Thought Leader Webinar Series; awareness materials and video

Drugs Available

STEP-TB Project aims to achieve the following goals

- Manufacturing and introduction of new pediatric formulations of existing first-line TB drugs
- Determine the core regulatory data required for approval of new pediatric medicines
- Creating evidence to inform the development of dosing guidelines for children weighing less than 5kg
- Planning for use of new regimens in children (i.e., Pa-M-Z, bedaquiline)



Key Product Information

□ Rifampicin 75 mg + Isoniazid 50 mg + Pyrazinamide 150 mg

Rifampicin 75 mg + Isoniazid 50 mg

- Availability: mid to late 2015 through Expert Review Panel (ERP) and through Global Drug Facility (at least one manufacturer)
- Registration: submit for WHO Prequalification by early 2015 (at least two manufacturers); pursue local registrations in parallel
- Formulation: dispersible; flavors—mango, strawberry, raspberry
- Price: close to currently available pediatric products, dependent on anticipated volumes

Ethambutol 100 mg

Isoniazid 100 mg

- Availability/Registration: later timeline—6-12 months behind FDCs; one manufacturer committed
- Formulation: dispersible
- Price: close to currently available products, dependent on anticipated volumes

Drugs Available

Progress to Date

- Delineating the registration requirements in the target markets for the new pediatric formulations
- Conducting the pharmacokinetics study of firstline treatment at current dosing recommendations in infants less than 12 months
- Planning for a consensus panel on the use of moxifloxacin in children to be held in mid-2015
- Partnering with Janssen on the pediatric development of bedaquiline
- Outlining an accelerated pediatric development pathway for new pediatric medicines and regimens currently in the pipeline



Uptake Influenced

STEP-TB Project aims to achieve the following goals

- Identify and map pediatric TB purchaser landscape
- Encourage widespread adoption of pediatric treatment guidelines, development of national guidelines and training tools
- Encourage use of new formulations
- Identify and reduce barriers to product uptake
- Work with countries to include childhood TB into national strategies/plans, budgets, and grant applications/renewals
- Identify funding sources to procure new pediatric formulations

Uptake Influenced

Progress to Date


- WHO issued comprehensive Childhood TB guidelines and training materials
- Held two consultations to set priorities and develop action plans for childhood TB
 - Western Pacific Region (WPR): 8 countries were represented
 - Eastern Mediterranean (EMR), South East Asia (SEAR) Regions (with select WPR countries): 11 countries were represented
- Continued collaboration with the Global Drug Facility (GDF) to prepare for the introduction of the new pediatric formulations
- Several efforts underway to ensure countries are including pediatric TB in GFATM concept notes
- Engagement of the Global Fund, other donors, and partners with in-country experience in product introduction



MANDATE (Maternal and Neonatal Directed Assessment of Technology) was built because there was NO quantitative process currently exists to evaluate and prioritize technology development options based on the potential to save maternal, fetal and newborn lives in low-resource settings.

MAPIT (MODEL FOR ASSESSMENT OF PEDIATRIC INTERVENTIONS FOR TUBERCULOSIS)

Where and how to allocate resources to have the greatest impact on Pediatric TB morbidities and mortalities?



Provide a tool for quantitative assessment of where innovation might have the greatest potential to reduce pediatric TB morbidity and mortality

TB ALLIANCE

Video: Anatomy of Neglect

- Click the link below to view the video:
 - <u>https://www.youtube.com/watch?v=o8zr5OMcuok</u>



Thank you!

For more information on childhood TB go to: tballiance.org/children

